Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05165316

European Long-acting Antipsychotics in Schizophrenia Trial-II

Schizophrenia is a chronic psychiatric illness with a heterogeneous disease course, varying from periods of symptomatic remission to relapse. Relative to the wealth of scientific data on the course of schizophrenia during the two years following the first psychotic episode, the outcome of schizophrenia patients over the first decade of their illness has been studied to a lesser degree. In this follow-up cohort study the aim is to investigate the long-term outcome of schizophrenia patients who participated in the previously conducted EULAST-I clinical trial, in the first decade after being diagnosed.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tel Hashomer The Sheba Medical Center

Ramat Gan, Israel

About this study

At this point, given the heterogeneity of published studies, it remains unclear if depot medication can reduce relapse rates and improve clinical outcome when offered to all patients in need of continuation treatment with antipsychotics. Before anyone can conclude whether or not all schizophrenia patients could benefit from a switch to depot formulations, several questions remain to be answered. Is depot medication associated with better continuation rates and outcome? How are depot medications tolerated as compared to oral medication? In order to clarify these important issues this study aims to perform a large multi-center trial in which schizophrenia patients in need of continuous treatment who are randomized 1:1:1:1 to two different depot preparations or to two different oral medications; patients will be followed up for a total of 19 months.

The primary objective of this trial is to compare all cause discontinuation rates in patients with schizophrenia randomized to oral antipsychotic medications (i.e., aripiprazole or paliperidone) versus depot antipsychotic medications (i.e., paliperidone palmitate or aripiprazole depot) over an 18 month follow-up period.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capable of providing written informed consent / have a legal representative to provide written informed consent. *
  • Having been randomized to one of the four treatment arms (aripiprazole oral, aripiprazole depot, paliperidone oral, paliperidone depot) in the 2014-002765-30 EULAST-I clinical trial or having participated in the EULAST-I naturalistic cohort study.
  • Unless prohibited by local law (e.g. due to incarceration).

Exclusion criteria

No exclusion criteria are applicable in this study.

Treatment and study plan

Primary outcomes

  1. To assess which baseline EULAST-I clinical trial baseline characteristics predict healthcare utilization (defined as number of days hospitalized) over a period of 3 - 10 years (since the EULAST-I clinical trial baseline visit).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

Secondary outcomes

  1. To provide insight into long-term social functioning as measured through the Personal and Social Performance (PSP) scale.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  2. To provide insight into long-term sociodemographic outcome (living circumstances, education, marital status).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  3. To provide insight in changes in neuropsychiatric diagnoses as measured through the Mini-International Neuropsychiatric Interview 7.0.2 (M.I.N.I. 7.0.2) since the EULAST-I clinical trial screening visit.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  4. To provide insight in long-term outcome in quality of life as measured through the Euroqol quality of life scale (EQ-5D-5L).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  5. To provide insight in long-term outcome in alcohol and drug use as well as smoking as measured through the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  6. To provide insight in long-term outcome of tardive dyskinesia as measured through the Abnormal and Involuntary Movement Scale (AIMS).

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  7. To provide insight in long-term outcome of extrapyramidal symptoms as measured through the St. Hans rating scale.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  8. To provide insight in the use of antipsychotic medication and other medication since the previous EULAST-I clinical trial.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  9. To provide insight into the reasons for hospitalizations since the baseline visit of the previous EULAST-I clinical trial.

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

  10. To provide insight into the incidence of suicide attempts since the baseline visit of the previous EULAST-I clinical trial

    Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).

Sponsors and collaborators

Lead sponsor

Rene Kahn

Other

Registry information

Acronym: EULAST-II

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Dec 21, 2021
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.